Xiya Reagent:GlaxoSmithKline drops plan to sell off older drugs

发布时间：2026-02-19

GlaxoSmithKline drops plan to sell off older drugs business

LONDON (Reuters) - GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

"The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products," it said in a statement.

A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details.

People familiar with the situation said last month that several private equity firms and smaller drug companies were looking at the assets on the block, which had been expected to sell for more than $3 billion.

Bidders, who had been hoping to clinch a deal before the end of the year, included Apollo Global Management, Denmark's Lundbeck, and KKR, which teamed up with private Dutch-based specialty drugmaker Norgine, sources said.· 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   

· 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

 

上一篇：PPG再次宣布北美工业涂料产品提价
下一篇：西亚试剂：从单细胞到多细胞转变的最初关键步骤进化速度比此前认为得更快